Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

NEUROCOV · The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV

HORIZONStatus: SIGNED1 September 202231 August 2027EU funding €8,384,036Call HORIZON-HLTH-2021-DISEASE-04

The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.

Consortium · 12 organisations

coordinator

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV

DE · €1,840,030

participant

HELSINGIN YLIOPISTO

FI · €359,840

thirdParty

AZIENDA SOCIO-SANITARIA TERRITORIALE FATEBENEFRATELLI SACCO

IT

participant

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

DE · €277,000

participant

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

DE · €597,812

participant

BEN-GURION UNIVERSITY OF THE NEGEV

IL · €197,635

participant

UMEA UNIVERSITET

SE · €180,362

participant

STICHTING AMSTERDAM UMC

NL · €536,917

thirdParty

HUMANITAS MIRASOLE SPA

IT

participant

UNIVERSITA DEGLI STUDI DI MILANO

IT · €960,283

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €199,218

participant

FONDAZIONE HUMAN TECHNOPOLE

IT · €3,234,940

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.